File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
  • Basic View
  • Metadata View
  • XML View
TitleThe use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
 
AuthorsLiang, B3
He, ML5
Chan, Cy5
Chen, Yc5
Li, XP1
Li, Y3
Zheng, D4
Lin, MC2
Kung, HF5
Shuai, XT3
Peng, Y3
 
KeywordsCombined gene therapy
Glioma
In vivo gene transfer
Nonviral vector
PEI PEGylation
Tumor targeting
 
Issue Date2009
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/biomaterials
 
CitationBiomaterials, 2009, v. 30 n. 23-24, p. 4014-4020 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.biomaterials.2009.04.011
 
AbstractCombined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. © 2009 Elsevier Ltd. All rights reserved.
 
ISSN0142-9612
2013 Impact Factor: 8.312
 
DOIhttp://dx.doi.org/10.1016/j.biomaterials.2009.04.011
 
ISI Accession Number IDWOS:000267469300023
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLiang, B
 
dc.contributor.authorHe, ML
 
dc.contributor.authorChan, Cy
 
dc.contributor.authorChen, Yc
 
dc.contributor.authorLi, XP
 
dc.contributor.authorLi, Y
 
dc.contributor.authorZheng, D
 
dc.contributor.authorLin, MC
 
dc.contributor.authorKung, HF
 
dc.contributor.authorShuai, XT
 
dc.contributor.authorPeng, Y
 
dc.date.accessioned2010-09-06T06:19:55Z
 
dc.date.available2010-09-06T06:19:55Z
 
dc.date.issued2009
 
dc.description.abstractCombined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. © 2009 Elsevier Ltd. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationBiomaterials, 2009, v. 30 n. 23-24, p. 4014-4020 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.biomaterials.2009.04.011
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.biomaterials.2009.04.011
 
dc.identifier.epage4020
 
dc.identifier.hkuros156070
 
dc.identifier.isiWOS:000267469300023
 
dc.identifier.issn0142-9612
2013 Impact Factor: 8.312
 
dc.identifier.issue23-24
 
dc.identifier.openurl
 
dc.identifier.pmid19427690
 
dc.identifier.scopuseid_2-s2.0-67349190843
 
dc.identifier.spage4014
 
dc.identifier.urihttp://hdl.handle.net/10722/70121
 
dc.identifier.volume30
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/biomaterials
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofBiomaterials
 
dc.relation.referencesReferences in Scopus
 
dc.rightsBiomaterials. Copyright © Elsevier BV.
 
dc.subjectCombined gene therapy
 
dc.subjectGlioma
 
dc.subjectIn vivo gene transfer
 
dc.subjectNonviral vector
 
dc.subjectPEI PEGylation
 
dc.subjectTumor targeting
 
dc.titleThe use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Liang, B</contributor.author>
<contributor.author>He, ML</contributor.author>
<contributor.author>Chan, Cy</contributor.author>
<contributor.author>Chen, Yc</contributor.author>
<contributor.author>Li, XP</contributor.author>
<contributor.author>Li, Y</contributor.author>
<contributor.author>Zheng, D</contributor.author>
<contributor.author>Lin, MC</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Shuai, XT</contributor.author>
<contributor.author>Peng, Y</contributor.author>
<date.accessioned>2010-09-06T06:19:55Z</date.accessioned>
<date.available>2010-09-06T06:19:55Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Biomaterials, 2009, v. 30 n. 23-24, p. 4014-4020</identifier.citation>
<identifier.issn>0142-9612</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/70121</identifier.uri>
<description.abstract>Combined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in&#160;vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. &#169; 2009 Elsevier Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/biomaterials</publisher>
<relation.ispartof>Biomaterials</relation.ispartof>
<rights>Biomaterials. Copyright &#169; Elsevier BV.</rights>
<subject>Combined gene therapy</subject>
<subject>Glioma</subject>
<subject>In vivo gene transfer</subject>
<subject>Nonviral vector</subject>
<subject>PEI PEGylation</subject>
<subject>Tumor targeting</subject>
<title>The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0142-9612&amp;volume=23-24&amp;spage=4014&amp;epage=4020&amp;date=2009&amp;atitle=The+Use+of+Folate-PEG-grafted-hybranched-PEI+Nonviral+Vector+for+the+Inhibition+of+Glioma+Growth+in+the+Rat</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.biomaterials.2009.04.011</identifier.doi>
<identifier.pmid>19427690</identifier.pmid>
<identifier.scopus>eid_2-s2.0-67349190843</identifier.scopus>
<identifier.hkuros>156070</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-67349190843&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>30</identifier.volume>
<identifier.issue>23-24</identifier.issue>
<identifier.spage>4014</identifier.spage>
<identifier.epage>4020</identifier.epage>
<identifier.isi>WOS:000267469300023</identifier.isi>
<publisher.place>Netherlands</publisher.place>
</item>
Author Affiliations
  1. Nanfang Hospital
  2. The University of Hong Kong
  3. Sun Yat-Sen University
  4. Chinese Academy of Medical Sciences
  5. Chinese University of Hong Kong